Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Griffin P. Rodgers, MD, MACP
Researcher Director
National Institute of Diabetes
and Digestive and Kidney Diseases
Building 31, Room 9A52
31 Center Drive
Bethesda, Maryland, United States
Dr. Griffin Rodgers, Director of the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases, is an accomplished clinician, researcher, and mentor, and is a role model.
His research interests include genetic diseases: sickle cell anemia, thalassemia, red cell enzymopathies; clinical evaluation of disease severity; treatment, including pharmacological alteration of gene expression and stem cell transplantation; molecular genetics of human hemoglobins; gene expression and differentiation in erythroid cells in normal and perturbed hematopoietic states; pharmacological alteration of gene expression; molecular genetics of myleodysplastic and myleoproliferative syndromes; hematopoiesis; role of inducible and stochastic factors; hematopoietic stem cell plasticity; identification of early markers of lineage-specific differentiation; the development of novel gene therapy strategies and their targeted application in cord blood hematopoietic stem cells.
As a research investigator, Dr. Rodgers is widely recognized for his contributions to the development of hydroxyurea, the first effective—and now FDA approved—therapy for sickle cell anemia.
Representative Publications:
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease
HbA2 : biology, clinical relevance and a possible target for ameliorating sickle cell disease
Hemolytic anemia-associated pulmonary hypertension in sickle cell disease
+myBinderRelated Content
-
Charles T. Quinn, MD, MSDr. Quinn is Associate Professor of clin...
-
International Association of Sickle Cell Nurses and Professional AssociatesThe International Association of Sickle ...
-
Johns Hopkins Berman Institute of BioethicsEstablished in 1995, the Berman Institut...
-
Provider Perspectives of Necessary Factors in Sickle Cell Disease Health Care Transition: Results from an Online Sur...Introduction: Survivorship of children w...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
-
Matthew Karafin, MD, MSMatthew Karafin, MD, MS is the associate...
-
Our healthcare system abandons adult sickle cell patientsWhen Janoi Burgess was a child, he thoug...
